U.S. FDA issues VAI classification to Granules arm Virginia facility
The U.S. FDA has issued a Voluntary Action Indicated (VAI) classification to Granules Pharmaceuticals' facility in Virginia following an inspection. This classification indicates that while minor issues were found, the regulator does not require immediate administrative or regulatory action.
Why it matters
This provides regulatory clarity for the company's manufacturing operations, preventing potential supply chain disruptions for its pharmaceutical products.
The U.S. Food and Drug Administration (U.S. FDA) has issued an establishment inspection report (EIR) with a voluntary action indicated (VAI) classification to the Granules Pharmaceuticals Inc. (GPI) facility in Chantilly, Virginia.
The report is a factual summary of a regulatory filing and market impact.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in